Genotype-Phenotype Classification of Triple Negative Breast Cancers (TNBC) in Women of African Descent Using the PAM50 NanoString Platform and Genomic.

Slides:

Advertisements

Similar presentations

Triple-Negative Breast Cancer

Advertisements

Carolina Breast Cancer Study: Breast cancer subtypes and race Robert Millikan University of North Carolina Chapel Hill, NC.

Introduction to Genomics, Bioinformatics & Proteomics Brian Rybarczyk, PhD PMABS Department of Biology University of North Carolina Chapel Hill.

Understanding and Optimizing Treatment of Triple Negative Breast Cancer Edith Peterson Mitchell, MD, FACP Clinical Professor of Medicine and Medical Oncology.

The 12-gene DCIS Score Assay and Quantitative Gene Expression for ER, PR, and HER2: Experience with 3,947 Patients Alvarado MD, 1 Tan V, 2 Bailey H, 2.

Expression profiling of peripheral blood cells for early detection of breast cancer Introduction Early detection of breast cancer is a key to successful.

Results grade1 grade2 grade3 (1) Can we identify metabolites or metabolic pathways that are associated with breast cancer clinical parameters? Alex-CIS-GCTOF.

A 14-gene prognosis signature predicts metastasis risk in node-negative, estrogen receptor-positive, Tamoxifen-treated breast cancer in different ethnogeographic.

Enabling biomarker validation in breast cancer molecular subtypes: sensitivity and specificity of array-based subtype classification in 983 patients Balázs.

Molecular classification of renal cell carcinoma subtypes using microRNA signatures Zaravinos A 1, Lambrou GI 2, Mourmouras N 3, Delakas D 3, Deltas C.

Introduction Results Material and Methods Conclusions Genetic variants predict clinical outcome clinical outcome in patients (pts) with metastatic colorectal.

Cancer Stem Cell SNPs Have Opposite Prognostic Outcome in Patients with Gastric Cancer Among Asian and Western Countries Melissa J. LaBonte 1, Takeru Wakatsuki.

Breast cancer in elderly patients (70 years and older): The University of Tennessee Medical Center at Knoxville 10 year experience Curzon M, Curzon C,

Snyder D, Heidel RE, Panella T, Bell J, Orucevic A University of Tennessee Medical Center – Knoxville Departments of Pathology, Surgery, and Medicine BREAST.

The International Consortium. The International HapMap Project.

High risk premenopausal Luminal A breast cancer patients derive no benefit from adjuvant chemotherapy: results from DBCG77B randomized trial 1 San Antonio.

San Antonio Breast Cancer Symposium – December 6-10, 2016

Prognostic impact of Ki-67 in Croatian women with early breast cancer (single-institution prospective observational study) Ivan Bilić, Natalija Dedić Plavetić,

014 - Evaluation of Immunosignature Profile in Medulloblastoma

TCGA, African-American (n= 129,%)

TRIPLE NEGATIVE BREAST CANCER (TNBC) & ETHNIC MINORITIES

Supplementary Figure 1 A B C.

Nurdianah HF, Nizuwan A, Muhamad Yusri M

Cancer Genomics and Class Discovery

Fig 2. IHC staining with MMR Proteins

Figure 2. DNA methylation mediated MORT gene silencing is linked to luminal, receptor positive breast cancers. (A) MORT expression level plotted versus.

Transcriptional heterogeneity of breast cancer subtypes,

Reproduced with permission from Cronin M et al

Luminal A normal-like Figure S12: KNN graph analysis showed that the cancer data consists of a series of connected, bifurcating clusters. luminal B normal.

Picture 3. Higher grade tumors are more frequently Ki67 positive

Hallett, et al., - Supplementary Figure 1

Figure S1. DCYTB expression is higher in ER+ than ER- patients

Comparison of Clinical Targeted Next-Generation Sequence Data from Formalin-Fixed and Fresh-Frozen Tissue Specimens David H. Spencer, Jennifer K. Sehn,

DNA Extraction of Lung Cancer Samples for Advanced Diagnostic Testing

A Targeted High-Throughput Next-Generation Sequencing Panel for Clinical Screening of Mutations, Gene Amplifications, and Fusions in Solid Tumors Rajyalakshmi.

Application of Selected Reaction Monitoring for Multiplex Quantification of Clinically Validated Biomarkers in Formalin-Fixed, Paraffin-Embedded Tumor.

Comprehensive Screening of Gene Copy Number Aberrations in Formalin-Fixed, Paraffin-Embedded Solid Tumors Using Molecular Inversion Probe–Based Single-

Analytical Validation of a Next-Generation Sequencing Assay to Monitor Immune Responses in Solid Tumors Jeffrey M. Conroy, Sarabjot Pabla, Sean T. Glenn,

MAGEA3 Expression in Cutaneous Squamous Cell Carcinoma Is Associated with Advanced Tumor Stage and Poor Prognosis Melody Abikhair, Nazanin Roudiani,

Quantitative Expression Profiling in Formalin-Fixed Paraffin-Embedded Samples by Affymetrix Microarrays Diana Abdueva, Michele Wing, Betty Schaub, Timothy.

Loyola Marymount University

European Urology Oncology

Genomic alterations in non–small cell lung cancer, breast cancer, and colorectal cancer. Genomic alterations in non–small cell lung cancer, breast cancer,

Tumor intrinsic subtype is reflected in cancer-adjacent tissue.

Accurate Classification of Germinal Center B-Cell–Like/Activated B-Cell–Like Diffuse Large B-Cell Lymphoma Using a Simple and Rapid Reverse Transcriptase–Multiplex.

Distribution of intrinsic subtypes among TNBC and distribution of TNBC among basal-like breast cancer. Distribution of intrinsic subtypes among TNBC and.

Diagnostics and Prognostics

Supplementary Figure 1 A B C.

Quality Assurance of RNA Expression Profiling in Clinical Laboratories

Down-regulation of LATS1 promotes the formation of tumors enriched in basal-like features. Down-regulation of LATS1 promotes the formation of tumors enriched.

Treated with Neoadjuvant Therapy

Loyola Marymount University

LATS2-associated gene expression pattern is down-regulated specifically in lumB breast tumors. LATS2-associated gene expression pattern is down-regulated.

Breast Cancer Subtype Identification Using RNA-Seq Data

Correlation between Pten/p53 status and AKT pathway activity in BC and effect on clinical outcome Box plot for p53‐pathway activity in p53 wild‐type and.

Loyola Marymount University

The Cancer genome atlas (TCGA) and the search for a CUP genetic/epigenetic signature Manel Esteller, MD, PhD. Director, Josep Carreras Leukaemia Research.

Figure 1. Identification of three tumour molecular subtypes in CIT and TCGA cohorts. We used CIT multi-omics data ( Figure 1. Identification of.

Loyola Marymount University

PD-L1 expression correlates with T-cell markers and an IFN response signature in human melanomas. PD-L1 expression correlates with T-cell markers and an.

EN1 expression in breast cancer and clinical outcome.

Targetable alterations and pathways in TNBCs after NAC

Clustering analysis of DTC-associated genes.

Defining the eTME genes.

Volume 28, Issue 3, Pages e7 (July 2019)

Subtype classification of breast functional screening results.

Highly metastatic PDAC cells have a unique gene signature, which is not preserved in metastases but predicts poor patient outcome. Highly metastatic PDAC.

MammaPrint and BluePrint Molecular Diagnostics Using Targeted RNA Next-Generation Sequencing Technology Lorenza Mittempergher, Leonie J.M.J. Delahaye,

Asociación entre el ARNm de PD1 y la respuesta a tratamiento con anti-PD1 en monoterapia en múltiples tipos de cánceres Tomás Pascual*, Laia Paré*, Elia.

Presentation transcript:

Genotype-Phenotype Classification of Triple Negative Breast Cancers (TNBC) in Women of African Descent Using the PAM50 NanoString Platform and Genomic Data Oluwasola A Olayiwola1, Temidayo Ogundiran2, Ashley Hardeman3, Toshio F Yoshimatsu3, Wendy Clayton3, Adewumi Adeoye1, Adeyinka Ademola2, Mustapha Ajani1, Galina Khramtsova3, Tatyana A Grushko3, Dezheng Huo4, Yonglan Zheng3, Joel Parker5, Charles Perou5, Olufunmilayo I Olopade3 1 Department of Pathology, 2 Department of Surgery, University College Hospital, Ibadan, Nigeria; 3 Center for Clinical Cancer Genetics and Global Health, 4 Department of Public Health Sciences, University of Chicago, Chicago IL, USA; 5 Lineberger Comprehensive Cancer Center, University of North Carolina-Chapel Hill, Chapel Hill NC, USA Abstract No. P6-04-05 Introduction Results 1% 5% HER2 LumB LumA Normal Basal Subtype Color Key Unclassified It is known that women of African descent are two to three times more likely to develop aggressive forms of breast cancer compared to women of European ancestry, yet wide-scale genomic studies of African and African American breast tumors are limited. To elucidate genotypes and molecular subtypes associated with the most aggressive forms of breast cancer, we used the PAM50 NanoString platform to reclassify Nigerian (NG), African American (AA) and Caucasian (CA) tumors clinically annotated by Immunohistochemistry (IHC) in the past. This work is the first step of our continued effort to correlate our findings to their germline genotype data obtained using high-throughput technologies. Confidence Subtype NG Cohort AA Cohort CA Cohort High Confidence ≥ 0.95 Low Confidence < 0.95 Confidence Color Key Basal-like Luminal A Luminal B HER2 Enriched Normal Subtype Color Key -3.0 Low Expression +3.0 High Expression Expression Level Scale A. C. B. Materials + Methods Samples : Formalin-fixed, paraffin embedded (FFPE) tumor tissues were collected at University College Hospital, Ibadan, Nigeria and the University of Chicago Medical Center, Chicago IL, USA after consenting patients to participate in the study. Blood DNAs were also obtained from each patients where available. 338 samples were prospectively collected on consecutive cases between 2003-2014 in Nigeria (NG). 73 samples from women with European ancestry (CA), and 92 samples from African American women (AA) were retrieved from the University of Chicago breast SPORE tumor repository in Chicago. Germline DNA from the cases were included in GWAS using Illumina 2.5 duo chip assay to determine germline genotypes. IRB protocols were approved by the Institutional Review Board of respective institutions prior to consenting patients. RNA Extraction and Molecular Subtyping by PAM50 RNAs were isolated from formalin-fixed, paraffin embedded (FFPE) tumor tissues using the High Pure Paraffin Kit (Roche) following manufacturer’s protocol. Prior to extraction, all samples were verified for its purity by reviewing a freshly prepared H&E slide. Macrodissection was performed to enrich for tumor cells for samples with less than 100 mm2 tumor surface area. Isolated RNAs were analyzed for their purity and content using NanoDrop. Molecular subtyping of tumors were performed on NanoString nCounter Analysis System using a custom Nano110 (PAM50 + claudin-low & VEGF signatures) probe set following the manufacturer’s protocol. Data quality was checked based on the expression levels of endogenous controls, negative controls, and deviation of global expression level from the median. Intrinsic subtyping were evaluated using custom script written for R statistical software. All study samples were clinically annotated and subtyped by the ER/PR/HER2 IHC classifier. Discussion Figure 1: Distribution of PAM50 subtypes in different population cohorts. (A) HER2 enriched, Basal-like, and Normal breast-like subtypes are known aggressive subtypes. Majority of NG cohort (52%) belong to these aggressive forms of breast cancer. The US samples was a convenient cohort and does not reflect consecutive cases. (B) Previously published distribution of breast cancer subtypes by IHC across multiple ethnicities (Huo D, et al. JCO 27:4515-21, 2009). Concordance of distribution as observed by IHC and PAM50 is consistent for Nigerians. (C) Heat map showing unsupervised clustering of PAM50 gene expression of NG, AA, and CA cohorts. Confidence of subtyping calls and intrinsic molecular subtyping calls by PAM50 is shown using color keys on the top two rows of the figure. To date, Intrinsic molecular subtyping by Nano110 has been completed on 162 NG, 92 AA and 74 CA tumors. Concordance between IHC and PAM50 was 54%, which is adequate and comparable to previous studies. There was a high proportion of basal-like and HER2 subtype and accounted for nearly 35% of NG and 30% of AA cases, Both IHC and PAM50 subtyping demonstrate population difference in subtype frequencies in this highly selected cohort. Larger sample size is required to examine association of subtypes with germline genotypes. PAM50 NanoString assay is reliable and high-throughput for molecular subtyping breast cancer using RNA extracted from FFPE tumors. Ongoing work will correlate PAM50 intrinsic subtypes to genotype data. A. B. PAM50 PAM50 Subtype Basal HER2 LumA LumB Normal Total 17 (58.62%) 1 (3.45%) 7 (24.14%) 3 (10.34%) 29 (100%) (0.00%) (25.00%) (75.00%) 4 2 (11.11%) 13 (72.22%) (5.56%) 18 Unclassified 19 (33.33%) (3.51%) (50.88%) 5 (8.77%) 57 Subtype Basal HER2 LumA LumB Normal Total 123 (84.83%) 10 (6.90%) 3 (2.76%) 1 (0.69%) 7 (4.83%) 145 (100%) 6 (16.67%) 29 (80.56%) (0.00%) (2.78%) 36 25 (3.61%) 8 (1.15%) 474 (68.40%) 163 (23.52%) 23 (3.32%) 693 5 (4.42%) 21 (18.58%) 49 (43.36%) (31.86%) 2 (1.77%) 113 159 (16.11%) 68 (6.89%) 526 (53.39%) 200 (20.26%) 33 (3.34%) 986 IHC IHC Figure 2. Concordance between PAM50 and IHC subtyping. Subtyping by IHC is based on interpretation of Estrogen Receptor (ER), Progesterone Receptor (PR), and HER2 expression positivity/negativity. The tumors were subtyped Luminal A (LumA) if ER+/PR+/HER2-; Luminal B (LumB ) if ER+/PR+/HER2+; HER2-enriched (HER2) if ER-/PR-/HER2+; and Basal-like (Basal) if ER-/PR-/HER2-. Percentage inside the parenthesis are raw percentages. (A) IHC data were collected from clinic in Nigeria, and only 57 samples had IHC data available. Concordance of IHC subtype to PAM50 subtype performed on the same samples show overall concordance of 54.4% (Cramer’s V statistics = 0.35 ; Pearson Chi2 = 28.3, P=0.0291). (B) Similar concordance test performed on The Cancer Genome Atlas (TCGA) data set of all population. IHC subtyping were done using the same criteria used in (a), and PAM50 subtyping calls were taken from TCGA data set. Overall concordance between TCGA IHC subtype to PAM50 subtype was 67% (Cramer’s V statistics = 0.58; Pearson Chi2 = 1.0e+03, P<0.0001) Acknowledgement This work was funded by NCI 3U01CA161032-02S1 awarded to DH and OIO; NCI U01 Supplement Grant awarded to AH and OIO; and Susan G Komen for the Cure grant awarded to OIO.